Nobivac® DHP Injectable live vaccine for dogs containing attenuated canine distemper virus, canine adenovirus (CAV-2) and canine parvovirus (C154). Active ingredients

For the active immunisation of dogs to reduce clinical signs of disease caused by canine distemper virus infection; to prevent clinical signs and viral excretion caused by canine parvovirus infection; to reduce clinical signs of canine contagious hepatitis and viral excretion due to canine adenovirus 1 infection and to reduce clinical signs of r...

Nobivac DHP vaccine provides core immunisation to dogs for distemper, hepatitis (canine adenovirus) and canine parvovirus. It is typically given in combination with a Nobivac …

administration in the Nobivac range against infectious tracheobronchitis caused by Bordetella bronchiseptica and/or canine parainfluenza virus. Revised: January 2025

Nobivac® DHP. By Company. Nobivac® DHP. MSD Animal Health UK Limited. Tel: 01908 685685 (Customer Support Centre) Datasheet & Company Info. Nobivac® DHP; Qualitative and quantitative composition; Pharmaceutical form; Clinical particulars; Pharmacological particulars; Pharmaceutical particulars;

【作用与用途】 用于预防犬的犬瘟热、传染性肝炎、细小病毒病和副流感。 【用法与用量】 皮下注射。 用疫苗稀释液稀释后，每只接种1头份。 每年进行1次副流感的加强接种，每2～3年进行1次犬瘟热、传染性肝炎、细小病毒病的加强接种。 【不良反应】 接种疫苗后偶见轻微过敏反应，一般情况下可自行消失。 （1）仅用于接种健康犬。 （2）不得用于接种肉用犬。 （3）可用于怀孕犬和哺乳犬。 （5）本品不要冻结，不要将疫苗长时间或反复暴露在高温条件下。 （6）疫苗 …

Nobivac® DHPPi Injectable live vaccine for dogs containing attenuated canine distemper virus, canine adenovirus (CAV-2), canine parvovirus (C154) and canine parainfluenza virus. Active Ingredients

What does Nobivac DHP provide protection against? What is the interval for Nobivac DHP for a puppy under 10 weeks of age?

What does Nobivac DHPPi provide protection against? To prevent mortality and clinical signs caused by canine distemper virus infection. To reduce clinical signs of infectious hepatitis and …

For active immunisation of dogs to prevent mortality and clinical signs caused by canine distemper virus infection. To reduce clinical signs of infectious hepatitis and viral excretion due to canine adenovirus type 1 infection. To prevent mortality, clinical signs and viral excretion following canine parvovirus infection.